Summary Tumour was obtained from 37 patients with oestrogen receptor-positive breast cancer, before and during treatment with tamoxifen, and examined qualitatively and semi-quantitatively for mRNA of the three mammalian TGF-/ isoforms. Levels of TGF-3 isoforms were then correlated with tumour response to tamoxifen, as assessed by monthly ultrasound. A high incidence of expression of each isoform was found in tumour material taken both before and during treatment. (Stewart, 1989 ), it appears that the primary effects of tamoxifen are modulated by competitive antagonism of oestrogen at its receptor (Katzenellenbogen et al., 1983; Berthois et al., 1986) . However, anti-tumour effects may be mediated secondarily through the action of inhibitory growth factors such as the transforming growth factor betas (TGFfls) (Butta et al., 1992). TGF-#s have been reported to be inhibitory to breast epithelial cells Travers et al., 1988; Barrett-Lee et al., 1990; Knabbe et al., 1991; Mizukami et al., 1991) , and their expression in breast tissues can be modified by tamoxifen (Salomon et al., 1989; Colletta et al., 1990; Sporn et al., 1990; McCune et al., 1992; Butta et al., 1992; Ji et al., 1994 Rougeon (1980) . Tumour tissue (minimum 0.2 g) was dismembranated and resuspended in 3 M lithium chloride-6 M urea (6 ml) before being sonicated and left overnight at 4°C to allow nucleic acids to precipitate. Total mRNA was then recovered by centrifugation (15 000 g) and digested in 10 mM Tris/sodium dodecyl sulphate (SDS) (6 ml) containing proteinase K (50 ,ug ml-'). Protein was removed using 100% phenol (pre-equilibrated with 0.1M Tris, pH 7.4), followed by phenol-chloroform-isoamyl alcohol 25:24:1, v/v/v) Bartlett et al., (1992) . Sample probe hybrids remaining after digestion with RNAase were denatured and separated by gel electrophoresis. Autoradiographs of the paired RNA samples were assessed by scanning densitometry for changes in expression of the three isoforms occurring during treatment with tamoxifen.
Tamoxifen is widely used in the treatment of postmenopausal breast cancer. Because benefits are usually observed in patients with oestrogen receptor-positive tumours (Stewart, 1989 ), it appears that the primary effects of tamoxifen are modulated by competitive antagonism of oestrogen at its receptor (Katzenellenbogen et al., 1983; Berthois et al., 1986) . However, anti-tumour effects may be mediated secondarily through the action of inhibitory growth factors such as the transforming growth factor betas (TGFfls) (Butta et al., 1992) . TGF-#s have been reported to be inhibitory to breast epithelial cells Travers et al., 1988; Barrett-Lee et al., 1990; Knabbe et al., 1991; Mizukami et al., 1991) , and their expression in breast tissues can be modified by tamoxifen (Salomon et al., 1989; Colletta et al., 1990; Sporn et al., 1990; McCune et al., 1992; Butta et al., 1992; Ji et al., 1994) . However, TGF-# can also act in a stimulatory fashion (Torre-Amione et al., 1990; Arrick et al., 1992; Arteaga et al., 1993; Chang et al., 1993) , and high levels of TGF-,B mRNA and protein have been associated with poor prognosis in patients with breast cancer King et al., 1989; Colletta, 1990; Welch et al., 1990; Thompson et al., 1991; Gorsch et al., 1992; Walker and Dearing, 1992; MacCallum et al., 1994; Walker et al., 1994) .
Assessments of the role of TGF-,Bs in the behaviour of breast cancer are also complicated by factors such as (1) TGF-f3 may be synthesised in one cell type and have its action in another (Lafyatis et al., 1990; Jackowlew et al., 1992) Rougeon (1980) . Tumour tissue (minimum 0.2 g) was dismembranated and resuspended in 3 M lithium chloride-6 M urea (6 ml) before being sonicated and left overnight at 4°C to allow nucleic acids to precipitate. Total mRNA was then recovered by centrifugation (15 000 g) and digested in 10 mM Tris/sodium dodecyl sulphate (SDS) (6 ml) containing proteinase K (50 ,ug ml-'). Protein was removed using 100% phenol (pre-equilibrated with 0.1M Tris, pH 7.4), followed by phenol-chloroform-isoamyl alcohol 25:24:1, v/v/v) Bartlett et al., (1992) . Sample probe hybrids remaining after digestion with RNAase were denatured and separated by gel electrophoresis. Autoradiographs of the paired RNA samples were assessed by scanning densitometry for changes in expression of the three isoforms occurring during treatment with tamoxifen.
Quantitation
Densitometry results were normalised to actin controls, and changes in expression of TGF-,B mRNA defined using several controls. These included (1) replicates of the tumour pairs run on different occasions, to assess reproducibility of measurements (greatest variation+68%); (2) different RNA extracts of the same tumour to determine heterogeneity within the tumour sample (greatest variation+66%); and (3) three patients studied sequentially over 3-7 weeks without intervening therapy to assess variations associated with no treatment (greatest variation+91%). An arbitrary cut off value of+ 100% was chosen to define any changes as significant and attributable to tamoxifen therapy.
Statistical analysis
Analysis of the results generated was carried out using the chi-squared test for trend. The expression of mRNA for the three isoforms of TGF-,B in pretreated and treated tumour samples is shown in Table I. TGF-fl, was expressed in all tumours before treatment, but following therapy, two cancers lost expression (one responding and one non-responding tumour). TGF-32 was expressed initially by 33 of 37 tumours, and during treatment in 35 of 37 (this included 32 of the tumours which initially showed expression); TGF-#3 expression was detected in 36 of 37 pretreatment and in all post-treatment samples. Therapy had no significant effects on the incidence of expression of TGF-fB isoforms within the total group, or between subgroups of responding and non-responding patients.
Quantitative analysis
Limits for normal variations in the expression of TGF-# were determined using several controls (see Materials and methods); changes in excess of+ 100% were regarded as substantial and potentially attributable to tamoxifen treatment. The autoradiograph in Figure 1 shows typical examples of tumours studied before and after treatment with tamoxifen; paired RNA samples being hybridised to a TGF-#2 probe. Patient 1 illustrates substantially increased expression with treatment, patient 2 very little change in expression, and in patient 3, a substantial decrease in level of expression with treatment. As is shown in Table II , the majority of tumours showed no substantial changes with treatment for TGF-fl, and -/33 expression, and those that did were as likely to display an increase as a decrease. For TGF-/2, more tumours showed changes in expression, these being predominantly increased expression after treatment.
When tumours were subdivided into responding and nonresponding groups, no significant associations were found between groups for changes in expression of TGF-1l3 and -/3 mRNA. However, there was a significant association between increasing expression of TGF-/32 and response (P= 0.018, chisquared test for trend); indeed no non-responding patients showed an increase in TGF-fl2, whereas 11 of 27 responding did so.
Discussion
The management of patients with primary systemic therapy provides the opportunity to monitor the effects of treatment TGF-P2 Butta et al., 1992; Jordan et al., 1993) , it should be noted that the effect on protein is on the /3, isoform, whereas the mRNA affected in the present study is TGF-/32. The present study provides evidence of differential regulation of different isoforms of TGF-,B, in (Ji et al., 1994) , which depend on other mechanisms, for example, the presence and concentration of other growth factors or cytokines within the tumour environment (Pepper et al., 1993) . Indeed there is accumulating evidence that with progression to more advanced disease resistance to TGF-#s can develop (Schultz and Grant, 1991; Kerbel et al., 1993) 
